Efficacy and safety of ravidasvir plus sofosbuvir in patients with chronic hepatitis C infection without cirrhosis or with compensated cirrhosis (STORM-C-1): interim analysis of a two-stage, open-label, multicentre, single arm, phase 2/3 trial

The findings of the first stage of this study in Malaysia and Thailand found ravidasvir plus sofosbuvir was effective (sustained virological response at 12 weeks after treatment in 97%) and well tolerated in a diverse adult population of patients with chronic HCV infection.

Source:

The Lancet Gastroenterology and Hepatology